Stratos Wealth Partners’s Gain Therapeutics GANX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-200,000
Closed -$406K – 1749
2026
Q2
$406K Buy
200,000
+68,379
+52% +$126K ﹤0.01% 1246
2026
Q1
$255K Buy
+131,621
New +$286K ﹤0.01% 1414

Other funds holding GANX

Stratos Wealth Partners's GANX Position: Q3 2026 in Review

Stratos Wealth Partners sold out of Gain Therapeutics (GANX) in Q3 2026, closing a stake of 200,000 shares — an estimated $406K sold.

Stratos Wealth Partners first reported a position in GANX in Q1 2026 and held it in 2 quarters. The position peaked at $406K in Q2 2026. 50 funds tracked by Wall St. Rank hold GANX as of Q3 2026.

  • Stratos Wealth Partners reported no remaining Gain Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Stratos Wealth Partners sold 200,000 Gain Therapeutics shares in Q3 2026, an estimated $406K.
  • Stratos Wealth Partners first reported a position in Gain Therapeutics in Q1 2026 and held it in 2 quarters.
  • Stratos Wealth Partners's Gain Therapeutics position peaked at $406K in Q2 2026.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2026.

Based on Stratos Wealth Partners's 13F filing for Q3 2026, filed 13 Nov 2026.